Ealixir

Ealixir Gross Profit

The Gross Profit of Ealixir (EAXR) as of Oct 19, 2026 is 2.67 M USD. In the previous year, Gross Profit was 1.41 M USD — a change of 89.36% (higher).

Gross Profit

2.67 MUSD

YoY

89.36%

Last updated:

Gross Profit of Ealixir is 2021 2.67 M USD. Gross Profit of Ealixir was 2020 1.41 M USD. It decreases by 89.36% higher compared to the previous year.

The Ealixir Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2007
905,000.00 USD
Jan 1, 2008
-876,000.00 USD
Jan 1, 2009
-659,000.00 USD
Jan 1, 2010
1.56 M USD
Jan 1, 2011
532,600.00 USD
Jan 1, 2012
731,700.00 USD
Jan 1, 2020
1.41 M USD
Jan 1, 2021
2.67 M USD
The Ealixir Gross Profit history
YEARGross ProfitYoY
2.67 MUSD+89.36%
1.41 MUSD+92.70%
731,700.00USD+37.38%
532,600.00USD-65.94%
1.56 MUSD-337.25%
-659,000.00USD-24.77%
-876,000.00USD-196.80%
905,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ealixir Revenue

Ealixir Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2007
966,000.00 USD
-989,000.00 USD
-2.12 M USD
Jan 1, 2008
3.15 M USD
-3.54 M USD
-3.86 M USD
Jan 1, 2009
34.34 M USD
-10.79 M USD
-14.56 M USD
Jan 1, 2010
34.06 M USD
-6.71 M USD
-28.87 M USD
Jan 1, 2011
15.79 M USD
-4.74 M USD
-10.66 M USD
Jan 1, 2012
10.75 M USD
-1.48 M USD
-307,000.00 USD
Jan 1, 2020
0.00 USD
-447,000.00 USD
-631,000.00 USD
Jan 1, 2021
3.53 M USD
0.00 USD
124,000.00 USD

Ealixir Margins

Ealixir stock margins

The Ealixir margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ealixir. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ealixir.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2007
93.69 %
-102.38 %
-219.46 %
Jan 1, 2008
-27.84 %
-112.43 %
-122.70 %
Jan 1, 2009
-1.92 %
-31.41 %
-42.41 %
Jan 1, 2010
4.59 %
-19.69 %
-84.75 %
Jan 1, 2011
3.37 %
-30.04 %
-67.54 %
Jan 1, 2012
6.81 %
-13.75 %
-2.86 %
Jan 1, 2020
75.64 %
- %
- %
Jan 1, 2021
75.64 %
0.00 %
3.51 %

Ealixir Stock analysis

What does Ealixir do? Ealixir Inc is a biotechnology company founded in 2012 by Dr. Nithin Rajan. Dr. Rajan earned his doctoral degree in biomedical science from the University of Ottawa and has over ten years of experience in the field of biomedical research. Ealixir Inc is an innovative firm specializing in the development of novel therapeutic technologies based on cell and proteomic research. Ealixir's goal is to help patients with serious or chronic illnesses by offering biological solutions that support the body's natural functions. Ealixir has developed the concept of "lifestyle medicine," aiming to develop treatments that not only combat diseases but also influence the patient's lifestyle to help them lead a healthier life. The company follows an integrative approach, combining the use of medications and other therapeutic approaches. Ealixir specializes in ingredients and technologies that have the potential to stimulate and activate the body to promote natural regenerative processes. One of Ealixir's significant products is the Arthritin system, which is used for the treatment of arthritis and pain. Arthritin utilizes a blend of pain relief, inflammation inhibitors, and regeneration promoters to effectively alleviate arthritis pain and reverse the damage caused by the disease to the joints. Ealixir is also a pioneer in the development of nano "in-minutes" technologies, where nanoparticles are used to actively transport active substances to specific target cells, thereby achieving results in minutes rather than hours. Another important product of Ealixir is Collagenix, a beauty product that uses a blend of collagen, vitamins, and minerals to improve skin structure and wrinkle depth. Ealixir also offers products for animal care and medicine. The company has developed a new product for wound care in pets using the Ealixir technology. The solution consists of antibacterial ingredients and promotes the growth of new tissue. Ealixir also focuses on researching dietary supplements that contribute to overall health and well-being. The company pays special attention to proteins, magnesium, and omega-3 fatty acids. The range includes CBD oil and support for restful sleep. Overall, Ealixir has established itself as a leading company in biomedical research and the development of innovative therapies. The company's products are at the forefront of technology and are developed and tested by a great team of researchers and scientists. The brand has experienced rapid growth in recent years and will undoubtedly achieve many successes in the future, benefiting both patients and animal lovers as well as people who value health and wellness. Ealixir is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ealixir stock

Gross Profit of Ealixir is 2.67 M USD in 2021.

Gross Profit of Ealixir changed from 1.41 M USD to 2.67 M USD, representing a 89.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Ealixir since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Ealixir historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Ealixir

All Key Metrics — Ealixir